KRAS and neoplasm: While BRAF and KRAS mutations both lead to activation of the RAS-RAF-MEK-cascade, KRAS mutations occur during tumour progression in the classical pathway or suppressor pathway while BRAF mutations are initiating mutations in the sessile serrated pathway (Nakanishi et al. 2019).